^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    VTCN1 expression

    i
    Other names: VTCN1, V-Set Domain Containing T Cell Activation Inhibitor 1, B7-H4, B7H4, B7S1, V-Set Domain-Containing T-Cell Activation Inhibitor 1, Immune Costimulatory Protein B7-H4, B7 Superfamily Member 1, B7 Family Member, H4, B7 Homolog 4, FLJ22418, B7h.5, B7x, T Cell Costimulatory Molecule B7x, T-Cell Costimulatory Molecule B7x, Protein B7S1, PRO1291, VCTN1, B7X
    Entrez ID:
    79679
    Related biomarkers:
    Expression
    Others
    19d
    Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. (PubMed, JCO Precis Oncol)
    Significant differences in GA and immune biomarkers are noted between IDH1/2+ and IDHwt iCCA. IDH1-/2-mutated tumors appear immunologically cold without gLOH. These immunogenomic data provide insight for precision targeting of iCCA with IDH alterations.
    Journal • Retrospective data • Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • HRD (Homologous Recombination Deficiency) • PD-1 (Programmed cell death 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD70 (CD70 Molecule)
    |
    PD-L1 expression • MSI-H/dMMR • IDH1 mutation • HRD • VTCN1 underexpression • IDH1 R132C • IDH wild-type • IDH1 R132 • VTCN1 expression • IDH1 R132L • IDH2 R140 • IDH2 R172
    |
    PD-L1 IHC 22C3 pharmDx
    2ms
    DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications. (PubMed, Eur J Med Res)
    Our data suggest that the detection of somatic mutations in DDR genes can predict the efficacy of immunotherapy in patients with ccRCC. Furthermore, we revealed the unique molecular and immune mechanisms underlying ccRCC with DDR gene mutations.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD70 (CD70 Molecule) • ICAM1 (Intercellular adhesion molecule 1)
    |
    IDO1 expression • VTCN1 expression
    6ms
    Immune Landscape in PD-L1-positive and TROP2-positive Triple-Negative Breast Cancer (SABCS 2023)
    The recent approvals and data of pembrolizumab (anti-PD-1 inhibitor) in combination with chemotherapy in advanced-metastatic and early high-risk TNBC, and sacituzumab govitecan (an ADC that targets the tumor cell surface antigen TROP2 coupled with the irinotecan metabolite SN-38) in metastatic TNBC, has shed light on some of the immune and cancer signaling associated with TNBC. This preliminary analysis confirmed that only a limited number of early TNBC highly expressed PD-L1 and that a different immune suppressive landscape for PD-L1± and TROP2± tumors exists. In addition, our data suggest that early TNBC cases lacking PD-L1 might escape immune surveillance by virtue of the upregulation of key alternate signaling. Ongoing efforts investigating the expression of such markers on stroma/epithelial tumor components will help to clarify their biological, clinical, and potential therapeutic role in TNBC.
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • STAT1 (Signal Transducer And Activator Of Transcription 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression • PD-L1 overexpression • HER-2 expression • PD-L1 underexpression • TROP2 expression • VTCN1 underexpression • TROP2 positive • VTCN1 expression • PD-L1-L
    |
    Keytruda (pembrolizumab) • irinotecan • Trodelvy (sacituzumab govitecan-hziy)